by Kevin Dooley, MD | Mar 27, 2020 | News and Information
Thomas Blaettler, MD, the Chief Medical Office of Orphazyme, has released a statement to the global community regarding the status of the ongoing arimoclomol clinical trials during the coronavirus (COVID-19) pandemic. Arimoclomol is currently being studied for... 
by Kevin Dooley, MD | Dec 18, 2019 | News and Information
Arimoclomol, an investigational drug currently in a Phase 2/3 trial for inclusion body myositis (IBM), has received Fast Track designation from the FDA for treatment of this disabling muscle disease. This designation is designed to shorten the time needed for the FDA... 
by Kevin Dooley, MD | Mar 27, 2019 | News and Information
Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually... 
by Kevin Dooley, MD | Jan 1, 2018 | News and Information
His muscles are being destroyed by a disease called inclusion body myositis (IBM), but Martin Jarry is resilient. After recovering from the shock of his diagnosis, he began to fight back, working to increase public awareness of myositis and to bring hope to other...